Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks

YokoeI.; NishioS.; SatoH.; KobayashiH.

首页> 外文期刊>Modern rheumatology >Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks

【24h】

Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks

机译：托珠单抗或英夫利昔单抗治疗12周后类风湿关节炎MMP-3水平的比较

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Rheumatoid arthritis (RA) is a common autoimmune disease characterized by persistent synovitis and progressive destruction of cartilage and bone in multiple joints. The affected joints exhibit hyperplasia of inflamed synovium infiltrated with a range of immune cells. Recently, biologic agents, as represented by tumor necrosis factor (TNF) inhibitors and a humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody, have been administered to RA patients with moderate to severe disease activity. Accumulating evidence attests to the excellent performance of biologies in reducing synovial inflammation and preventing joint destruction. Three TNF inhibitors (inflix-imab INF; etanercept ETN and adalimumab ADA) and one IL-6 inhibitor (tocilizumab TCZ) are approved and used in Japan.

机译：类风湿关节炎（RA）是一种常见的自身免疫性疾病，其特征是持续性滑膜炎以及多关节中软骨和骨骼的逐渐破坏。受影响的关节表现出由一系列免疫细胞浸润的发炎的滑膜增生。近来，以肿瘤坏死因子（TNF）抑制剂和人源化抗人白细胞介素6（IL-6）受体单克隆抗体为代表的生物制剂已被施用于患有中度至重度疾病活动的RA患者。越来越多的证据证明了生物制剂在减少滑膜炎症和预防关节破坏方面的出色表现。在日本已批准并使用三种TNF抑制剂（英夫利昔单抗INF;依那西普ETN和阿达木单抗ADA）和一种IL-6抑制剂（托珠单抗TCZ）。

著录项

来源
《Modern rheumatology》 |2011年第6期|共5页
作者
YokoeI.; NishioS.; SatoH.; KobayashiH.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病;
关键词
Interleukin-6 (IL-6); Matrix metalloproteinase-3 (MMP-3); Tumor necrosis factor (TNF);

机译：白细胞介素6（IL-6）;基质金属蛋白酶3（MMP-3）;肿瘤坏死因子（TNF）;

相似文献

外文文献
中文文献
专利

1. Comment on "Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks" by Yokoe et al. [J] . NagashimaT., OkazakiH., KamataY., Modern rheumatology . 2012,第4期

机译：Yokoe等人评论“类风湿关节炎中MMP-3水平在接受托珠单抗或英夫利昔单抗治疗12周后的比较”。
2. Reply to: Comment on "Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks" by Yokoe et al. [J] . YokoeI., NishioS., SatoH., Modern rheumatology . 2012,第4期

机译：回复：Yokoe等人评论“类风湿关节炎MMP-3水平在接受Tocilizumab或Infliximab治疗12周后的比较”。
3. Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks [J] . YokoeI., NishioS., SatoH., Modern rheumatology . 2011,第6期

机译：托珠单抗或英夫利昔单抗治疗12周后类风湿关节炎MMP-3水平的比较
4. Hyaluronic Acid-Gold Nanoparticle-Tocilizumab Complex for the Treatment of Rheumatoid Arthritis [C] . Hwiwon Lee, Min-Young Lee, Ki Su Kim, Society for biomaterials annual meeting and exposition . 2013

机译：透明质酸-金纳米颗粒-托珠单抗复合物治疗类风湿关节炎
5. The Efficacy of Therapeutic Drug Monitoring of Rheumatoid Arthritis Patients on Infliximab [D] . Abolhosn, Rania. 2018

机译：类风湿性关节炎患者治疗药物监测对英夫利昔单抗的疗效
6. Erratum to Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients [O] . Sang Jin Lee, Won Park, Sung Hwan Park, 2017

机译：勘误表低基线白细胞介素17A水平与类风湿关节炎患者在第12周接受Tocilizumab治疗的治疗反应更好相关
7. A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period [O] . Atsushi Ogata, Yoshiya Tanaka, Tomonori Ishii, 2017

机译：随机，双盲，并行组，第三阶段研究缩短了类风湿性关节炎患者的皮下对硅酸化单药治疗的剂量间隔及对皮下丁证的反应不足：12周双盲期的结果

Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks

摘要

著录项

相似文献

相关主题

期刊订阅